Lars Engstrom
6PUBLICATIONS
81CO-AUTHORS
Get your video featured.
Publish with JoVEGet your video featured.
Publish with JoVE
Publications (6)
Sort by Publication Date:
|Jul 22, 2025
Combination of the MTA-Cooperative PRMT5 Inhibitor BMS-986504 and KRAS Inhibitors Is an Effective Treatment Strategy for MTAP-Deleted KRAS-Mutant Pancreatic Cancer.Kristina Drizyte-Miller, Lars D Engstrom, Jeffrey A Klomp
|Jan 13, 2025
Impact of Co-mutations and Transcriptional Signatures in Non-Small Cell Lung Cancer Patients Treated with Adagrasib in the KRYSTAL-1 Trial.Marcelo V Negrao, Alvaro G Paula, David Molkentine
|Jun 21, 2024
The SOS1 Inhibitor MRTX0902 Blocks KRAS Activation and Demonstrates Antitumor Activity in Cancers Dependent on KRAS Nucleotide Loading.Niranjan Sudhakar, Larry Yan, Fadia Qiryaqos
|Aug 08, 2023
MRTX1719 Is an MTA-Cooperative PRMT5 Inhibitor That Exhibits Synthetic Lethality in Preclinical Models and Patients with MTAP-Deleted Cancer.Lars D Engstrom, Ruth Aranda, Laura Waters
|Oct 10, 2022
Anti-tumor efficacy of a potent and selective non-covalent KRASG12D inhibitor.Jill Hallin, Vickie Bowcut, Andrew Calinisan
|Mar 16, 2021
The KRASG12C Inhibitor MRTX849 Reconditions the Tumor Immune Microenvironment and Sensitizes Tumors to Checkpoint Inhibitor Therapy.David M Briere, Shuai Li, Andrew Calinisan
Pageof 1
Frequent Collaborators
6 joint publications
Jill Hallin
5 joint publications
James G Christensen
4 joint publications
David M Briere
4 joint publications
Laura Waters
4 joint publications
Peter Olson
3 joint publications
Laura Hover
3 joint publications
J David Lawson
3 joint publications
Christopher R Smith
3 joint publications
Matthew A Marx
3 joint publications
Andrew Calinisan
